Eun Kyoung Choi1, Ari Chong2, Jung-Min Ha2, Chan Kwon Jung3, Joo Hyun O4, Sung Hoon Kim4. 1. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 2. Department of Nuclear Medicine, Chosun University Hospital, Gwangju, South Korea. 3. Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 4. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Abstract
OBJECTIVE: We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAF V600E mutation, using quantitative and qualitative analyses of preoperative PET/CT data. DESIGN AND PATIENTS: This was a retrospective review of 106 patients with PTC who underwent PET/CT scans between February 2009 and January 2011 before undergoing total thyroidectomy. Data collected from surgical specimens were compared with FDG uptake in the primary tumour using quantitative and qualitative analyses of preoperative PET/CT data. Clinicopathological data included the primary tumour size, subtype, capsular invasion, extrathyroid extension, multifocality, BRAF V600E mutation status, lymph node metastasis and distant metastasis. RESULTS: The SUVmax of the primary tumour was significantly higher in patients with a primary tumour >1 cm, extrathyroid extension or the BRAF V600E mutation than in patients without these features (P<.001, .049 and <.001). Univariate analyses showed that primary tumour size, extrathyroid extension and BRAF V600E mutation status were associated with the SUVmax of the PTC. Multivariate analysis indicated that primary tumour size and the BRAF V600E mutation were associated with the SUVmax of the PTC. In a visual assessment, the primary tumour size was larger in FDG-avid than in non-FDG-avid PTCs (P<.001). There was no significant difference in the presence of multifocality, thyroid capsular invasion, extrathyroid extension, BRAF V600E mutation, lymph node metastasis or distant metastasis between FDG-avid and non-FDG-avid PTCs. CONCLUSIONS: Primary tumour size and the BRAF V600E mutation are significant factors associated with the SUVmax on preoperative PET/CT in patients with PTC.
OBJECTIVE: We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAFV600E mutation, using quantitative and qualitative analyses of preoperative PET/CT data. DESIGN AND PATIENTS: This was a retrospective review of 106 patients with PTC who underwent PET/CT scans between February 2009 and January 2011 before undergoing total thyroidectomy. Data collected from surgical specimens were compared with FDG uptake in the primary tumour using quantitative and qualitative analyses of preoperative PET/CT data. Clinicopathological data included the primary tumour size, subtype, capsular invasion, extrathyroid extension, multifocality, BRAFV600E mutation status, lymph node metastasis and distant metastasis. RESULTS: The SUVmax of the primary tumour was significantly higher in patients with a primary tumour >1 cm, extrathyroid extension or the BRAFV600E mutation than in patients without these features (P<.001, .049 and <.001). Univariate analyses showed that primary tumour size, extrathyroid extension and BRAFV600E mutation status were associated with the SUVmax of the PTC. Multivariate analysis indicated that primary tumour size and the BRAFV600E mutation were associated with the SUVmax of the PTC. In a visual assessment, the primary tumour size was larger in FDG-avid than in non-FDG-avid PTCs (P<.001). There was no significant difference in the presence of multifocality, thyroid capsular invasion, extrathyroid extension, BRAFV600E mutation, lymph node metastasis or distant metastasis between FDG-avid and non-FDG-avid PTCs. CONCLUSIONS:Primary tumour size and the BRAFV600E mutation are significant factors associated with the SUVmax on preoperative PET/CT in patients with PTC.
Authors: Long Chen; Conghui Yang; Jun Feng; Xin Liu; Yadong Tian; Lei Zhao; Ran Xie; Chao Liu; Sheng Zhao; Hua Sun Journal: Cancer Manag Res Date: 2017-12-15 Impact factor: 3.989
Authors: Ellen C de Heer; Adrienne H Brouwers; Ronald Boellaard; Wim J Sluiter; Gilles F H Diercks; Geke A P Hospers; Elisabeth G E de Vries; Mathilde Jalving Journal: EJNMMI Res Date: 2018-11-20 Impact factor: 3.138
Authors: Le Ngoc Ha; Amir Iravani; Nguyen Thi Nhung; Ngo Thi Minh Hanh; Febby Hutomo; Mai Hong Son Journal: Cancer Imaging Date: 2021-01-07 Impact factor: 3.909